Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer

To understand the role of MALAT-1 in prostate cancer we evaluated its expression in prostate cancer tissues and cell lines. We also studied the therapeutic effects of MALAT-1 silencing on castration resistant prostate cancer cells in vitro and in vivo. Quantitative reverse transcriptase-polymerase c...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	The Journal of urology Ročník 190; číslo 6; s. 2278
Hlavní autori:	Ren, Shancheng, Liu, Yawei, Xu, Weidong, Sun, Yi, Lu, Ji, Wang, Fubo, Wei, Min, Shen, Jian, Hou, Jianguo, Gao, Xu, Xu, Chuanliang, Huang, Jiaoti, Zhao, Yi, Sun, Yinghao
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.12.2013
Predmet:	Animals Cell Cycle - genetics Humans Male Mice Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - genetics Prostatic Neoplasms, Castration-Resistant - metabolism RNA, Long Noncoding - biosynthesis RNA, Long Noncoding - genetics Tumor Cells, Cultured lncRNA RNA MALAT-1 siRNA-5 castration resistant prostate cancer M5 MALAT-1 siRNA-9 M9 reverse transcriptase-PCR LNCaP-AI RT-PCR long noncoding RNA CCK-8 small interfering LNCaP-androgen independent subtype human polymerase chain reaction PSA PBS MALAT1 long non-coding RNA prostate specific antigen Cell Counting Kit-8 phosphate buffered saline MALAT-1 prostatic neoplasms prostate antiandrogens metastasis associated in lung adenocarcinoma transcript 1 CRPC PCR
ISSN:	1527-3792, 1527-3792
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	To understand the role of MALAT-1 in prostate cancer we evaluated its expression in prostate cancer tissues and cell lines. We also studied the therapeutic effects of MALAT-1 silencing on castration resistant prostate cancer cells in vitro and in vivo. Quantitative reverse transcriptase-polymerase chain reaction was used to detect MALAT-1 expression in prostate cancer tissues and cell lines. siRNA against MALAT-1 was designed and the silencing effect was examined by quantitative reverse transcriptase-polymerase chain reaction. The biological effects of MALAT-1 siRNA on cells were investigated by examining cell proliferation using a cell counting kit and cell colony assays as well as cell migration by in vitro scratch assay, cell invasion by Transwell® invasion assay and cell cycle by flow cytometry. We further investigated the effect of therapeutic siRNA targeting MALAT-1 on castration resistant prostate cancer in vivo. MALAT-1 was up-regulated in human prostate cancer tissues and cell lines. Higher MALAT-1 expression correlated with high Gleason score, prostate specific antigen, tumor stage and castration resistant prostate cancer. MALAT-1 down-regulation by siRNA inhibited prostate cancer cell growth, invasion and migration, and induced castration resistant prostate cancer cell cycle arrest in the G0/G1 phases. Importantly, intratumor delivery of therapeutic siRNA targeting MALAT-1 elicited delayed tumor growth and reduced metastasis of prostate cancer xenografts in castrated male nude mice, followed by the concomitant prolongation of survival of tumor bearing mice. MALAT-1 may be needed to maintain prostate tumorigenicity and it is involved in prostate cancer progression. Thus, MALAT-1 may serve as a potential therapeutic target for castration resistant prostate cancer.
AbstractList	To understand the role of MALAT-1 in prostate cancer we evaluated its expression in prostate cancer tissues and cell lines. We also studied the therapeutic effects of MALAT-1 silencing on castration resistant prostate cancer cells in vitro and in vivo.PURPOSETo understand the role of MALAT-1 in prostate cancer we evaluated its expression in prostate cancer tissues and cell lines. We also studied the therapeutic effects of MALAT-1 silencing on castration resistant prostate cancer cells in vitro and in vivo.Quantitative reverse transcriptase-polymerase chain reaction was used to detect MALAT-1 expression in prostate cancer tissues and cell lines. siRNA against MALAT-1 was designed and the silencing effect was examined by quantitative reverse transcriptase-polymerase chain reaction. The biological effects of MALAT-1 siRNA on cells were investigated by examining cell proliferation using a cell counting kit and cell colony assays as well as cell migration by in vitro scratch assay, cell invasion by Transwell® invasion assay and cell cycle by flow cytometry. We further investigated the effect of therapeutic siRNA targeting MALAT-1 on castration resistant prostate cancer in vivo.MATERIALS AND METHODSQuantitative reverse transcriptase-polymerase chain reaction was used to detect MALAT-1 expression in prostate cancer tissues and cell lines. siRNA against MALAT-1 was designed and the silencing effect was examined by quantitative reverse transcriptase-polymerase chain reaction. The biological effects of MALAT-1 siRNA on cells were investigated by examining cell proliferation using a cell counting kit and cell colony assays as well as cell migration by in vitro scratch assay, cell invasion by Transwell® invasion assay and cell cycle by flow cytometry. We further investigated the effect of therapeutic siRNA targeting MALAT-1 on castration resistant prostate cancer in vivo.MALAT-1 was up-regulated in human prostate cancer tissues and cell lines. Higher MALAT-1 expression correlated with high Gleason score, prostate specific antigen, tumor stage and castration resistant prostate cancer. MALAT-1 down-regulation by siRNA inhibited prostate cancer cell growth, invasion and migration, and induced castration resistant prostate cancer cell cycle arrest in the G0/G1 phases. Importantly, intratumor delivery of therapeutic siRNA targeting MALAT-1 elicited delayed tumor growth and reduced metastasis of prostate cancer xenografts in castrated male nude mice, followed by the concomitant prolongation of survival of tumor bearing mice.RESULTSMALAT-1 was up-regulated in human prostate cancer tissues and cell lines. Higher MALAT-1 expression correlated with high Gleason score, prostate specific antigen, tumor stage and castration resistant prostate cancer. MALAT-1 down-regulation by siRNA inhibited prostate cancer cell growth, invasion and migration, and induced castration resistant prostate cancer cell cycle arrest in the G0/G1 phases. Importantly, intratumor delivery of therapeutic siRNA targeting MALAT-1 elicited delayed tumor growth and reduced metastasis of prostate cancer xenografts in castrated male nude mice, followed by the concomitant prolongation of survival of tumor bearing mice.MALAT-1 may be needed to maintain prostate tumorigenicity and it is involved in prostate cancer progression. Thus, MALAT-1 may serve as a potential therapeutic target for castration resistant prostate cancer.CONCLUSIONSMALAT-1 may be needed to maintain prostate tumorigenicity and it is involved in prostate cancer progression. Thus, MALAT-1 may serve as a potential therapeutic target for castration resistant prostate cancer. To understand the role of MALAT-1 in prostate cancer we evaluated its expression in prostate cancer tissues and cell lines. We also studied the therapeutic effects of MALAT-1 silencing on castration resistant prostate cancer cells in vitro and in vivo. Quantitative reverse transcriptase-polymerase chain reaction was used to detect MALAT-1 expression in prostate cancer tissues and cell lines. siRNA against MALAT-1 was designed and the silencing effect was examined by quantitative reverse transcriptase-polymerase chain reaction. The biological effects of MALAT-1 siRNA on cells were investigated by examining cell proliferation using a cell counting kit and cell colony assays as well as cell migration by in vitro scratch assay, cell invasion by Transwell® invasion assay and cell cycle by flow cytometry. We further investigated the effect of therapeutic siRNA targeting MALAT-1 on castration resistant prostate cancer in vivo. MALAT-1 was up-regulated in human prostate cancer tissues and cell lines. Higher MALAT-1 expression correlated with high Gleason score, prostate specific antigen, tumor stage and castration resistant prostate cancer. MALAT-1 down-regulation by siRNA inhibited prostate cancer cell growth, invasion and migration, and induced castration resistant prostate cancer cell cycle arrest in the G0/G1 phases. Importantly, intratumor delivery of therapeutic siRNA targeting MALAT-1 elicited delayed tumor growth and reduced metastasis of prostate cancer xenografts in castrated male nude mice, followed by the concomitant prolongation of survival of tumor bearing mice. MALAT-1 may be needed to maintain prostate tumorigenicity and it is involved in prostate cancer progression. Thus, MALAT-1 may serve as a potential therapeutic target for castration resistant prostate cancer.
Author	Shen, Jian Huang, Jiaoti Ren, Shancheng Sun, Yinghao Wei, Min Zhao, Yi Lu, Ji Xu, Weidong Liu, Yawei Hou, Jianguo Xu, Chuanliang Wang, Fubo Gao, Xu Sun, Yi
Author_xml	– sequence: 1 givenname: Shancheng surname: Ren fullname: Ren, Shancheng organization: Department of Urology, Shanghai Changhai Hospital, Second Military Medical University, Shanghai, People's Republic of China – sequence: 2 givenname: Yawei surname: Liu fullname: Liu, Yawei – sequence: 3 givenname: Weidong surname: Xu fullname: Xu, Weidong – sequence: 4 givenname: Yi surname: Sun fullname: Sun, Yi – sequence: 5 givenname: Ji surname: Lu fullname: Lu, Ji – sequence: 6 givenname: Fubo surname: Wang fullname: Wang, Fubo – sequence: 7 givenname: Min surname: Wei fullname: Wei, Min – sequence: 8 givenname: Jian surname: Shen fullname: Shen, Jian – sequence: 9 givenname: Jianguo surname: Hou fullname: Hou, Jianguo – sequence: 10 givenname: Xu surname: Gao fullname: Gao, Xu – sequence: 11 givenname: Chuanliang surname: Xu fullname: Xu, Chuanliang – sequence: 12 givenname: Jiaoti surname: Huang fullname: Huang, Jiaoti – sequence: 13 givenname: Yi surname: Zhao fullname: Zhao, Yi – sequence: 14 givenname: Yinghao surname: Sun fullname: Sun, Yinghao
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/23845456$$D View this record in MEDLINE/PubMed
BookMark	eNpNkE1LxDAQhoOsuB_6BzxIjl5ak7RJ2mNZ_IKqIOu5ZNPZNUs3qUmK-O8NqOBpHphn3oF3iWbWWUDokpKcEipuDvlh8i5nhBY5kTkh9AQtKGcyK2TNZv94jpYhHJJQcsnO0JwVVclLLhbItM7ucQrWrjeJXp8b_NS0zSaj2ASssIVPPLoINho14PgOXo0wRaNxVH4PEe-cx1qF6FU0zmIPwYSobMSjdwkipK3V4M_R6U4NAS5-5wq93d1u1g9Z-3L_uG7aTPOSxExLXYEU0Be0YEyVgtcF61VRybJWui6VUIz2QhChKyFBMyFlnw6KnkrJ-y1boeuf3PT_Y4IQu6MJGoZBWXBT6FIHhFa8EjypV7_qtD1C343eHJX_6v7qYd9oTWnc
CitedBy_id	crossref_primary_10_1038_s41585_019_0195_1 crossref_primary_10_1002_ddr_21924 crossref_primary_10_1158_1541_7786_MCR_14_0273 crossref_primary_10_1016_j_bbagrm_2015_09_012 crossref_primary_10_1016_j_prp_2023_154666 crossref_primary_10_2147_CMAR_S241093 crossref_primary_10_3390_molecules28052126 crossref_primary_10_3892_mmr_2019_10602 crossref_primary_10_1016_j_critrevonc_2024_104275 crossref_primary_10_1007_s12291_021_00999_6 crossref_primary_10_1016_j_cca_2017_08_009 crossref_primary_10_3389_fphar_2021_732266 crossref_primary_10_1016_j_juro_2017_04_061 crossref_primary_10_1042_BSR20150003 crossref_primary_10_1186_s12943_018_0852_7 crossref_primary_10_1016_j_cancergen_2016_09_005 crossref_primary_10_3892_or_2016_4909 crossref_primary_10_1007_s11255_017_1536_8 crossref_primary_10_1155_2014_765207 crossref_primary_10_1016_j_juro_2014_05_031 crossref_primary_10_1038_s41417_022_00487_w crossref_primary_10_3390_ncrna6020022 crossref_primary_10_3390_ijms26167667 crossref_primary_10_1002_pros_23538 crossref_primary_10_1016_j_biocel_2017_12_005 crossref_primary_10_1177_09636897221122997 crossref_primary_10_1101_gr_254656_119 crossref_primary_10_1186_s13287_017_0706_z crossref_primary_10_1016_j_canlet_2016_09_019 crossref_primary_10_1016_j_prp_2024_155455 crossref_primary_10_1186_s11658_023_00447_8 crossref_primary_10_1016_j_clgc_2024_102213 crossref_primary_10_3389_fonc_2017_00305 crossref_primary_10_3390_cancers12113086 crossref_primary_10_1074_jbc_M114_596866 crossref_primary_10_1093_nargab_lqac102 crossref_primary_10_3389_fonc_2024_1415801 crossref_primary_10_1007_s12038_018_9820_z crossref_primary_10_1038_modpathol_2014_75 crossref_primary_10_1002_cbf_3531 crossref_primary_10_1002_jcp_24918 crossref_primary_10_3892_mmr_2015_4711 crossref_primary_10_3892_ijmm_2017_2920 crossref_primary_10_1016_j_prp_2024_155226 crossref_primary_10_1016_j_molmed_2014_03_005 crossref_primary_10_1016_j_bbcan_2021_188612 crossref_primary_10_1186_s41021_022_00252_3 crossref_primary_10_1007_s13237_024_00503_4 crossref_primary_10_1007_s13277_016_5450_y crossref_primary_10_3390_cancers14051149 crossref_primary_10_1038_s41375_018_0104_2 crossref_primary_10_1038_srep46566 crossref_primary_10_3389_fcell_2023_1164301 crossref_primary_10_1042_BST20160428 crossref_primary_10_1002_mco2_141 crossref_primary_10_3390_biomedicines11020633 crossref_primary_10_1016_j_juro_2014_02_011 crossref_primary_10_1016_j_yexcr_2021_112909 crossref_primary_10_3389_fgene_2019_00769 crossref_primary_10_1038_s41419_022_04554_w crossref_primary_10_3727_096504017X14953948675403 crossref_primary_10_1002_jcp_26759 crossref_primary_10_1016_j_trsl_2017_03_005 crossref_primary_10_2217_pgs_2022_0077 crossref_primary_10_1016_j_mce_2018_10_023 crossref_primary_10_1016_j_dnarep_2021_103170 crossref_primary_10_3390_cancers14194877 crossref_primary_10_1016_j_bbcan_2021_188519 crossref_primary_10_1016_j_adcanc_2025_100132 crossref_primary_10_1016_j_eururo_2017_04_005 crossref_primary_10_1155_2022_8051717 crossref_primary_10_3390_genes9070345 crossref_primary_10_3389_fphar_2024_1483186 crossref_primary_10_1016_j_juro_2014_05_110 crossref_primary_10_1016_j_biopha_2020_110027 crossref_primary_10_1186_s13046_021_02233_w crossref_primary_10_1016_j_canlet_2020_11_040 crossref_primary_10_1016_j_cca_2017_08_038 crossref_primary_10_1038_cddis_2016_252 crossref_primary_10_1093_jjco_hyv214 crossref_primary_10_1093_nar_gkx1221 crossref_primary_10_1016_j_canlet_2016_03_003 crossref_primary_10_1186_s12859_019_3128_3 crossref_primary_10_3390_cancers11101524 crossref_primary_10_1016_j_cellsig_2022_110265 crossref_primary_10_1016_j_intimp_2020_106279 crossref_primary_10_1089_cbr_2014_1661 crossref_primary_10_1186_s12935_020_01280_1 crossref_primary_10_1007_s00424_016_1803_z crossref_primary_10_3389_fphar_2024_1442227 crossref_primary_10_1016_j_prp_2019_152649 crossref_primary_10_1007_s12020_015_0629_3 crossref_primary_10_1016_j_canlet_2019_08_010 crossref_primary_10_1097_CEJ_0000000000000433 crossref_primary_10_1016_j_juro_2013_09_016 crossref_primary_10_1016_j_urolonc_2021_11_012 crossref_primary_10_3389_fonc_2021_562378 crossref_primary_10_1002_jcb_27838 crossref_primary_10_1038_s41598_017_05274_4 crossref_primary_10_1186_s12967_024_05877_2 crossref_primary_10_1007_s10555_016_9628_y crossref_primary_10_1038_s41420_024_01930_7 crossref_primary_10_1016_j_juro_2016_12_031 crossref_primary_10_1016_j_biopha_2014_03_001 crossref_primary_10_1016_j_critrevonc_2021_103310 crossref_primary_10_1111_jcmm_12431 crossref_primary_10_1016_j_mam_2015_05_003 crossref_primary_10_3892_mmr_2015_3897 crossref_primary_10_3390_ijms19072120 crossref_primary_10_1002_1878_0261_12866 crossref_primary_10_1016_j_currproblcancer_2014_11_004 crossref_primary_10_1186_s12935_020_01363_z crossref_primary_10_1080_00365521_2017_1280531 crossref_primary_10_3389_fonc_2022_946060 crossref_primary_10_1016_j_canlet_2023_216247 crossref_primary_10_1007_s40291_017_0271_2 crossref_primary_10_3390_ijms160613322 crossref_primary_10_1016_j_ymthe_2025_07_037 crossref_primary_10_1007_s00210_024_03736_x crossref_primary_10_1002_pros_23367 crossref_primary_10_3390_life13122304 crossref_primary_10_25259_Cytojournal_36_2024 crossref_primary_10_1080_15548627_2019_1659614 crossref_primary_10_3390_ijerph14030270 crossref_primary_10_1158_1541_7786_MCR_23_0003 crossref_primary_10_3390_cells13242035 crossref_primary_10_1016_j_critrevonc_2022_103598 crossref_primary_10_1038_s41571_018_0035_x crossref_primary_10_3390_ijms161226138 crossref_primary_10_3390_ijms18020473 crossref_primary_10_1016_j_jpsychires_2023_06_017 crossref_primary_10_1155_2016_9085195 crossref_primary_10_3727_096504016X14549667334007 crossref_primary_10_1016_j_cca_2020_11_027 crossref_primary_10_1016_j_prp_2019_01_011 crossref_primary_10_1007_s12672_024_01458_3 crossref_primary_10_3390_ijms20010098 crossref_primary_10_1002_jcp_29775 crossref_primary_10_3390_cancers14030755 crossref_primary_10_3390_cancers13010015 crossref_primary_10_1016_j_prp_2024_155179 crossref_primary_10_1007_s10238_023_01179_x crossref_primary_10_1016_j_molmed_2018_01_001 crossref_primary_10_3390_ijms150813993 crossref_primary_10_1007_s11033_019_04810_x crossref_primary_10_1016_j_adcanc_2022_100067 crossref_primary_10_1186_s40591_015_0042_6 crossref_primary_10_1186_s12943_016_0545_z crossref_primary_10_1002_ijc_32422 crossref_primary_10_1016_j_urolonc_2020_06_003 crossref_primary_10_1038_pcan_2015_48 crossref_primary_10_1089_dna_2019_5247 crossref_primary_10_3892_ol_2018_8613 crossref_primary_10_3390_cancers14030749 crossref_primary_10_1038_s41419_020_02856_5 crossref_primary_10_1371_journal_pone_0152687 crossref_primary_10_1016_j_biopha_2019_109666 crossref_primary_10_1016_j_mam_2025_101359 crossref_primary_10_3390_diseases11020072 crossref_primary_10_1007_s44411_025_00219_0 crossref_primary_10_1002_ijc_34282 crossref_primary_10_1007_s13277_015_4261_x crossref_primary_10_1186_s12864_015_1881_x crossref_primary_10_1186_s13046_015_0123_z crossref_primary_10_1093_carcin_bgae021 crossref_primary_10_1186_s12885_016_2988_4 crossref_primary_10_1111_cas_13587 crossref_primary_10_1007_s12032_025_02859_2 crossref_primary_10_1111_cas_13352 crossref_primary_10_1371_journal_pone_0204912 crossref_primary_10_3390_diagnostics8030060 crossref_primary_10_3892_etm_2018_7142 crossref_primary_10_1016_j_cancergen_2020_02_007 crossref_primary_10_3892_etm_2019_7277 crossref_primary_10_3390_cancers14246043 crossref_primary_10_1186_s10020_018_0050_5 crossref_primary_10_1002_cam4_1384 crossref_primary_10_3389_fbioe_2020_00266 crossref_primary_10_1038_srep41179 crossref_primary_10_1016_j_tranon_2023_101807 crossref_primary_10_1007_s12032_014_0346_4 crossref_primary_10_3390_jcm8071033 crossref_primary_10_1002_ijc_30039 crossref_primary_10_1002_jor_23105 crossref_primary_10_1155_2014_591703 crossref_primary_10_1002_1873_3468_13182 crossref_primary_10_2147_CMAR_S276022 crossref_primary_10_3389_fonc_2019_00739 crossref_primary_10_3390_ijms24021305 crossref_primary_10_1038_s41419_021_03854_x crossref_primary_10_1186_s12918_018_0527_4 crossref_primary_10_1007_s13277_014_2636_z crossref_primary_10_1002_jcp_30393 crossref_primary_10_1002_jcp_27561 crossref_primary_10_1016_j_yexmp_2019_104330 crossref_primary_10_3892_ijmm_2019_4256 crossref_primary_10_1186_s12935_018_0606_z crossref_primary_10_3389_fchem_2024_1342178 crossref_primary_10_1158_1078_0432_CCR_18_0444 crossref_primary_10_1080_14737159_2023_2187289 crossref_primary_10_3390_genes8080207
ContentType	Journal Article
Copyright	Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
Copyright_xml	– notice: Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1016/j.juro.2013.07.001
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1527-3792
ExternalDocumentID	23845456
Genre	Research Support, Non-U.S. Gov't Journal Article
GroupedDBID	--- --K .55 .GJ .XZ 08P 0R~ 123 1B1 1CY 354 3O- 4.4 457 4G. 4Q1 4Q2 4Q3 53G 5RE 5VS 7-5 AAAAV AAEDT AAEDW AAGIX AAHPQ AAIQE AAJCS AAKAS AALRI AAMOA AAQFI AAQKA AAQQT AAQXK AASCR AASXQ AAXUO ABASU ABCQX ABDIG ABJNI ABLJU ABMAC ABOCM ABPPZ ABPXF ABVCZ ABWVN ABXYN ABZZY ACGFS ACILI ACLDA ACOAL ACRPL ACVFH ACXJB ACZKN ADCNI ADGGA ADGHP ADHPY ADMUD ADNKB ADNMO ADZCM AEBDS AEETU AENEX AFBFQ AFDTB AFEXH AFFNX AFNMH AFTRI AFUWQ AGHFR AGQPQ AHOMT AHQNM AHQVU AHRYX AHVBC AI. AIGII AINUH AITUG AIZYK AJCLO AJIOK AJNWD AJZMW AKCTQ AKULP ALKUP ALMA_UNASSIGNED_HOLDINGS ALMTX AMJPA AMKUR AMNEI AMRAJ AOQMC ASGHL ASPBG AVWKF AZFZN BCGUY BELOY BYPQX C45 C5W CGR CS3 CUY CVF DIWNM DU5 EBS ECM EEVPB EIF EJD ERAAH EX3 F5P FCALG FDB FEDTE FGOYB GBLVA GNXGY GQDEL HLJTE HVGLF HZ~ H~9 IH2 IHE IKREB IKYAY IPNFZ J5H KMI L7B M41 MJL MO0 N4W NPM NQ- NTWIH O9- OAG OAH OB3 OBH ODMTH OGROG OHH OL1 OVD OWU OWV OWW OWY OWZ P2P QTD R2- RIG RLZ ROL RPZ SEL SES SJN SSZ TEORI TSPGW UDS UNMZH UV1 VH1 VVN WOW X7M XH2 XYM YFH YOC ZCG ZFV ZGI ZXP ZY1 ZZMQN 7X8
ID	FETCH-LOGICAL-c540t-c7c8e76ed31322a465932da38749ac94a6a21d6606c867ec2677de763d1775db2
IEDL.DBID	7X8
ISICitedReferencesCount	287
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000327441000114&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1527-3792
IngestDate	Fri Sep 05 12:54:45 EDT 2025 Mon Jul 21 06:04:48 EDT 2025
IsPeerReviewed	true
IsScholarly	true
Issue	6
Keywords	lncRNA RNA MALAT-1 siRNA-5 castration resistant prostate cancer M5 MALAT-1 siRNA-9 M9 reverse transcriptase-PCR LNCaP-AI RT-PCR long noncoding RNA CCK-8 small interfering LNCaP-androgen independent subtype human polymerase chain reaction PSA PBS MALAT1 long non-coding RNA prostate specific antigen Cell Counting Kit-8 phosphate buffered saline MALAT-1 prostatic neoplasms prostate antiandrogens metastasis associated in lung adenocarcinoma transcript 1 CRPC PCR
Language	English
License	Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c540t-c7c8e76ed31322a465932da38749ac94a6a21d6606c867ec2677de763d1775db2
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
PMID	23845456
PQID	1450185865
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_1450185865 pubmed_primary_23845456
PublicationCentury	2000
PublicationDate	2013-12-01
PublicationDateYYYYMMDD	2013-12-01
PublicationDate_xml	– month: 12 year: 2013 text: 2013-12-01 day: 01
PublicationDecade	2010
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	The Journal of urology
PublicationTitleAlternate	J Urol
PublicationYear	2013
SSID	ssj0014572
Score	2.5668802
Snippet	To understand the role of MALAT-1 in prostate cancer we evaluated its expression in prostate cancer tissues and cell lines. We also studied the therapeutic...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	2278
SubjectTerms	Animals Cell Cycle - genetics Humans Male Mice Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - genetics Prostatic Neoplasms, Castration-Resistant - metabolism RNA, Long Noncoding - biosynthesis RNA, Long Noncoding - genetics Tumor Cells, Cultured
Title	Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer
URI	https://www.ncbi.nlm.nih.gov/pubmed/23845456 https://www.proquest.com/docview/1450185865
Volume	190
WOSCitedRecordID	wos000327441000114&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NS8MwFA_qRLz4_TG_iOC1uLRpkp5kiMPDVoZM2a2kSSbz0Na18-_3vbZjXgTBS6GUlJD3kV_y3vs9Qu6kNk6k1nnI5eRxCaaYBiAQEymte1IHrK6veBvKOFbTaTRuL9zKNq1y5RNrR21zg3fk94wj9VyoRPhQfHrYNQqjq20LjU3SCQDKoFbL6TqKwMO6eRN2bgVDivy2aKbJ7_pYLrD4jwU1eWeP_Q4x661msP_fSR6QvRZk0n6jFYdkw2VHZGfUhtGPyXyYZ-8UDv4mx62LvsR9OuoP-xOP0XlJNQWsTYu8wkwi-M-PGi3aZI5TgLrU6BXnLoUzO-LQrKIFVpEAfoWvoE6LE_I6eJo8PnttzwXPAHarPCONclI4i5SOvuYiBIBndaAkj7SJuBbaZ1bAsccoIZ3xhZQWBgSWSRna1D8lWzB9d04oqIGfqh7X4CP4jAmVOumsb1iqNLyZLrldLWICOo2BCp25fFkm62XskrNGEknRkG8kADE4or6LP4y-JLso4Cb75Ip0ZmDR7ppsm69qXi5uamWBZzwefQMAuMjp
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Long+noncoding+RNA+MALAT-1+is+a+new+potential+therapeutic+target+for+castration+resistant+prostate+cancer&rft.jtitle=The+Journal+of+urology&rft.au=Ren%2C+Shancheng&rft.au=Liu%2C+Yawei&rft.au=Xu%2C+Weidong&rft.au=Sun%2C+Yi&rft.date=2013-12-01&rft.eissn=1527-3792&rft.volume=190&rft.issue=6&rft.spage=2278&rft_id=info:doi/10.1016%2Fj.juro.2013.07.001&rft_id=info%3Apmid%2F23845456&rft_id=info%3Apmid%2F23845456&rft.externalDocID=23845456
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1527-3792&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1527-3792&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1527-3792&client=summon